Read the complete MedWatch 2008 Safety summary, including a link to the Dear Healthcare Professional letter and the December 2 FDA Ongoing Safety Review, at: http://www.fda.gov/medwatch/safety/2008/safety08.htm#Innohep
KCER strives to provide disaster preparedness resources to save lives, improve outcomes, empower patients and families, educate healthcare workers, build partnerships with stakeholders, promote readiness in the community, and support the ESRD Network Program.
Saturday, January 3, 2009
FDA Alert: Innohep (12/31/08)
Celgene has issued a Dear Healthcare Professional letter describing a controlled clinical study suggesting that Innohep may increase the risk for death, compared to unfractionated heparin when used to treat elderly patients with renal insufficiency. It recommended consideration of alternatives to Innohep when treating these patients for deep vein thrombosis with or without pulmonary embolism.